Wednesday, October 14, 2026

ServiceNow, HPE Deploy NVIDIA AI Agents as Enterprise Software Shifts to Autonomous Workflows

Major enterprises including ServiceNow, HPE, and World Kinect are deploying NVIDIA's AI agent technologies for production workflows, marking a shift from experimental to operational AI infrastructure. NVIDIA released multiple foundation models—Nemotron 3, Cosmos 3, Isaac GR00T, and Alpamayo 1.5—alongside specialized tools targeting autonomous enterprise operations. The convergence signals enterprise software transformation as companies replace manual processes with AI-driven agents.

LM Salvado
LM Salvado

March 21, 2026

Source Trace Score7 source documents7 with a live linkVerifiability: Strong
ServiceNow, HPE Deploy NVIDIA AI Agents as Enterprise Software Shifts to Autonomous Workflows
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

ServiceNow, HPE, and World Kinect are deploying NVIDIA AI agents for production workflows, moving enterprise artificial intelligence from pilot programs to operational infrastructure.1 The deployments leverage NVIDIA's recently released foundation models including Nemotron 3, Cosmos 3, Isaac GR00T, and Alpamayo 1.5.1

NVIDIA launched its Agent Toolkit and nvQSP pharmaceutical tool to support autonomous workflow deployment across enterprises.1 Companies including Distyl and Factory are adopting the technologies for agentic workflows that handle multi-step processes without human intervention.1

The enterprise AI shift contrasts with desktop-focused approaches from competitors like Skywork, which positions AI as an "always-available work layer for knowledge workers" that coordinates task completion within existing software environments.2 Skywork emphasizes on-device processing where "your data never leaves, security stays with you."2

Enterprise adoption centers on replacing manual coordination with autonomous agents that execute end-to-end workflows. ServiceNow's deployment targets IT service management automation, while HPE focuses on infrastructure management tasks that previously required multiple human touchpoints.1

The technology stack combines large language models with specialized reasoning capabilities. NVIDIA's Nemotron 3 and Cosmos 3 models provide foundation capabilities, while Isaac GR00T and Alpamayo 1.5 target specific industrial and analytical applications.1

Skywork plans "deeper integration into everyday work environments, stronger controls for organizations, and workflow capabilities that scale from individual productivity to team and enterprise use."2 This desktop-first strategy differs from NVIDIA's infrastructure-focused approach but addresses similar enterprise automation needs.

The pharmaceutical sector represents a key vertical, with NVIDIA's nvQSP tool designed specifically for drug development workflows.1 World Kinect's deployment targets energy trading and logistics operations that require real-time decision-making across complex supply chains.1

Enterprise software vendors are integrating AI agents as core platform features rather than add-ons, suggesting fundamental architecture changes. The shift from human-driven to agent-driven workflows requires new security models, governance frameworks, and operational protocols that major corporations are now deploying at scale.1

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score7 source documents7 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· February 4, 2026
    4 Internet Stocks Poised to Top Estimates This Earnings Season
  2. [2]Press releaseGlobeNewswire· February 6, 2026
    Skywork Launches Desktop AI Agent for Windows Productivity
  3. [3]News articleYahoo Finance· March 10, 2026
    Xanadu and AMD Accelerate Quantum Computing for Aerospace and Engineering
  4. [4]News articleYahoo Finance· March 16, 2026
    Adobe and NVIDIA Announce Strategic Partnership to Deliver the Next Generation of Firefly Models and Creative, Marketing and Agentic Workflows
  5. [5]Press releaseGlobeNewswire· March 16, 2026
    NVIDIA Expands Open Model Families to Power the Next Wave of Agentic, Physical and Healthcare AI
  6. [6]News articleYahoo Finance· March 16, 2026
    NVIDIA Ignites the Next Industrial Revolution in Knowledge Work With Open Agent Development Platform
  7. [7]News articleCrunchbase News
    The Rising Investors Behind The New Unicorn Class

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com